Chad M Robins sold $4.0M of ADPT
CEO and Chairman at Adaptive Biotechnologies Corp. 470,368 shares at an average of $8.47, traded Feb 13, 2025, filed Feb 18, 2025.
Score components
- +25RoleCEO
- +25Trade size$4.0M at market
- +5Share of holdings soldSold 18% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.3%, 3m +13.2%, 6m +51.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001062993-25-002744, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 13, 2025 | MOption exercise Common Stock10b5-1 | +100,287 | $6.32 | $634k | 2,676,988 | Feb 18, 2025 |
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -100,287 | $8.44 | $846k | 2,576,701 | Feb 18, 2025 |
| Feb 14, 2025 | MOption exercise Common Stock10b5-1 | +158,921 | $6.32 | $1.0M | 2,735,622 | Feb 18, 2025 |
| Feb 14, 2025 | SOpen-market sale Common Stock10b5-1 | -158,921 | $8.46 | $1.3M | 2,576,701 | Feb 18, 2025 |
| Feb 18, 2025 | MOption exercise Common Stock10b5-1 | +211,160 | $6.32 | $1.3M | 2,787,861 | Feb 18, 2025 |
| Feb 18, 2025 | SOpen-market sale Common Stock10b5-1 | -211,160 | $8.50 | $1.8M | 2,576,701 | Feb 18, 2025 |
| Feb 13, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -100,287 | $0.00 | $0 | 655,268 | Feb 18, 2025 |
| Feb 14, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -158,921 | $0.00 | $0 | 496,347 | Feb 18, 2025 |
| Feb 18, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -211,160 | $0.00 | $0 | 285,187 | Feb 18, 2025 |
Related signals
Other insiders at Adaptive Biotechnologies Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $920k 35,643 shares | -9% | |
| Pro nowfree Oct 15, 2026 | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $948k 35,643 shares | -9% | |
| Pro nowfree Oct 15, 2026 | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $193k 6,444 shares | -2% | |
| 22Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $758k 26,792 shares | -11% | |
| 25Weak | Adaptive Biotechnologies Corp | Julie Rubinstein President and COO | $1.0M 35,643 shares | -9% | |
| 23Weak | Adaptive Biotechnologies Corp | Francis Lo Chief People Officer | $3.2M 115,406 shares | -34% | |
| 8Weak | Adaptive Biotechnologies Corp | Susan Bobulsky Chief Commercial Officer, MRD | $32k 1,195 shares | -0% | |
| 48Moderate | Adaptive Biotechnologies Corp | Katey Einterz Owen director | $250k 9,615 shares | -11% | |
| 46Moderate | Adaptive Biotechnologies Corp | Robert Hershberg director | $748k 30,664 shares | -40% | |
| 50Moderate | Adaptive Biotechnologies Corp | Peter M Neupert director | $3.1M 124,690 shares | -49% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.